SCHEMBL3832735

SCHEMBL3832735

C1=CCC(c2n[nH]c3ncccc23)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 1/20 0.39
▸ AXL P30530 1/20 0.35
▸ AURKA O14965 1/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ GPR84 Q9NQS5 1/20 0.34
▸ PIK3CD O00329 1/20 0.33
▸ PIK3R1 P27986 1/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CHRNB2 P17787 2/20 0.32
▸ CHRNA7 P36544 2/20 0.32
▸ CHRNA4 P43681 2/20 0.32
▸ CYP2A6 P11509 1/20 0.32
▸ GRM4 Q14833 3/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ OPRL1 P41146 2/20 0.32
▸ OPRM1 P35372 1/20 0.32
▸ OPRK1 P41145 1/20 0.32
▸ RET P07949 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21733021 0.86 PDK2 (0.47) PDK2AXLAURKAPARP1GPR84
SCHEMBL17857651 0.81 HTR1A (0.40) PDK2CYP1A2HSD17B10
Hydrochloric Acid SCHEMBL17837567 0.80 HTR1A (0.40) PDK2CYP1A2HSD17B10
Hydrochloric Acid SCHEMBL17837407 0.80 HTR1A (0.40) PDK2CYP1A2HSD17B10
SCHEMBL10154478 0.79 SLC6A4 (0.38) PDK2AXLAURKAPARP1GPR84
SCHEMBL10154468 0.74 KMT2A (0.38) PDK2AXLAURKAPARP1GPR84
SCHEMBL10126647 0.73 MAPK1 (0.36) —
SCHEMBL18324978 0.72 GRM4 (0.52) GRM4CYP1A2KDM4E
SCHEMBL17524924 0.71 DRD4 (0.38) KMT2ACYP1A2RETDRD2DRD4
SCHEMBL29705459 0.70 GRM4 (0.38) PDK2GRM4OPRL1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648893-B1 NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS PFIZER PROD INC (US) 2009-09-23 — — EP disclosed
US-7456177-B2 Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy PFIZER INC. (US) 2008-11-25 — — US disclosed
EP-1648893-A1 NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS Pfizer Products Inc. (US) 2006-04-26 — — EP disclosed
WO-2005007655-A1 NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-01-27 — — WO disclosed
US-20050020830-A1 Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy PFIZER INC 2005-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020830-A1 Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy CHRNA2, CHRNA3, CHRNB2 PDK2 1464/4885AXL 753/4885AURKA 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback